Shasun Of India Sees Double Sales Selling Ingredients Of Expiring Drugs
This article was originally published in PharmAsia News
India's Shasun Pharmaceuticals expects to double its sales in the next three years based on supplying to generic drug makers the main ingredients for patent-losing drugs, such as of Pfizer's Advil (chlorpheniramine).
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.